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Abstract:

Folate receptor has achieved great importance for use in targeted drug delivery and in vitro
and in vivo diagnostic assays1-2. Folate receptor (FR) is over expressed on several cancer cell
types and activated macrophages, but exists in relatively low abundance on the surface of noncancerous tissue and non-inflammatory cells. This unique attribute is the hallmark of folate –
targeted methodologies allowing the diagnostic agent and/or drug to be ferried to the specific
disease sites while preventing “off target” effects in normal tissues3-4. Although several folatebased dyes have been reported, simple and detailed synthetic and purification methods for these
conjugates have not been reported. Our objective is to develop a new folate-based dye and the
corresponding HPLC methods for the purification and analysis of this conjugate. FolateDylightTM 800 was successfully synthesized by very simple, inexpensive and safe method. The
whole synthesis method can be performed in small laboratories with minimum resources and
small quantity of reagents required. The synthesis of Folate-DylightTM 800 conjugate was
successfully purified by HPLC. The purified Folate-DylightTM 800 conjugate was evaluated by
microplate reader, UV-Vis and HPLC.
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Introduction:

Folic Acid: (Figure: 1)
Folic acid or vitamin B9 is a water soluble vitamin. Folic acid from food and supplements
is biologically inactive in the body. The reduced form i.e. Tetrahydrofolate (THF), which is the
active form of Folic acid, plays a key role in the metabolic activity of the body. It is necessary
for the normal and healthy growth of cells because it acts as a coenzyme for DNA and RNA
synthesis.5-6 Folate is a vital nutrition for pregnant women as it helps in the reproduction of cells
and growth in the foetus. Deficiency of folic acid may result in improper effects on cell division
and protein synthesis and therefore causes impairment of growth. In the presence of Folic acid
and Cyanacobalmine (Vit B12) conversion of homocysteine to methionine takes place thereby
reducing the blood levels of homocysteine and thus decreasing the risk of heart related
problems.7 It maintains a healthy nervous system’s by involving in the production of
neurotransmitters

which regulate mood, sleep and appetite. It also prevents urinary tract

infections. Neural tube effects can be avoided if the pregnant women include folic acid into their
daily diet8-9. Low levels of folic acid may result in cancers of cervix, colon and lungs. Red blood
cells are particularly susceptible to folic acid deficiency; hence causing anaemia10. Folate also
plays a crucial role in the metabolism of many amino acids which include histidine, glycine and
methionine11.
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Folate receptor:
Folate receptors are present on the cell surface. They are surface glycoprotein with high
affinity for folic acid and folate, which capture the folate from the extracellular liquid and
transports to the cell11-12. The folate receptors are present on the normal cells, however there is
greater receptor presence on malignant cells coupled with the fact that only unique GPI
(glycosylphosphatidylinositol anchored folate receptor is the only form capable of uptake of
folate conjugated species (reduced folate carrier is incapable of uptake of folate conjugates). This
characteristic of malignant cells can be useful for the diagnosis of cancer13-14. Folate receptors
can be used for many kinds of folate conjugates like targeted drug delivery for cancer treatment
and attached conjugate will not release and will not be degraded. Within the endosome, the folate
imaging agent conjugate is released from the folate receptor.

Folate Conjugates:
Folate can be coupled with different molecules including chemotherapeutic agents, protein
toxins, immunotherapeutic agents, antisense oligonucleotides; liposomes entrapped drug,
polymeric drug carrier and imaging agents.15 Imaging agents can be conjugated to folic acid
using variety of linkers and cleavable bonds without affecting the binding affinity of the folate
moiety to the folate receptor. (Figure: 2 shows the schematic representation of folate-dye
conjugates) Peptides or carbon chain can be used as spacer depending upon the size of imaging
agent.16-17 Folate based conjugates have exceptionally good penetration power due to its low
molecular weight as compared to antibodies. Production cost of antibodies is very high which
leads to higher cost for in vivo as well as in vitro diagnosis.18
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Folate receptor pathway:
Folate-conjugates bind folate receptor with high affinity19-20 and are subsequently
engulfed in as endosomes and that can reduce disulfide bonds of the linkers. In the absence of
any cleavage of the bond, the attached conjugate will not release and will not be degraded.
Within the endosome, the folate imaging agent conjugate is released from the folate receptor
(Figure-3).

DylightTM 800 Maleimide:
The DyLightTM 800 belongs to DyLight line of fluorescent dyes which are fabricated
by Dyomics in collaboration with Thermo Fisher Scientific. DyLight dyes have a broad range of
application including in biotechnology and research applications as biomolecules, cell and tissue
labels for fluorescence related studies, cell biology or molecular biology.
Classical fluorophores such as fluorescein and Rhodamine have been used in a wide
range of applications. But these dyes have certain limitations for use in microscopy and other
applications that require exposure to an intense light source and high temperatures such as a
laser, because they photo-bleach very quickly. DyLight family of Fluorophors have similar
excitation and emission spectra and are exceptionally photostable, brighter, and less pH sensitive. The excitation and emission spectra of the DyLight Fluorophores series covers the
visible spectrum and also extends into the near infrared region, allowing detection using most of
the fluorescence microscopes, as well as special infrared imaging systems.
DylightTM 800 products (Table-1).
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DylightTM 800 properties and applications (Figure-4).
Thermo scientific Dylight 800 is near-IR flour that is invisible to the naked eye but increases
the staining options when using infrared imaging systems. Dylight 800 has spectral properties2124

which are very similar to other near-IR dyes, including Alexa Fluor*790 and IR*Dye 800, and

has high solubility for maximal incorporation into the biomolecule of interest.22-23

Physical properties of Thermo Scientific DyLightTM 800 dye:27-29
Physical characteristics of Thermo Scientific DylightTM 800 dye, including excitation/emission
spectra, emitted color, extinction coefficient, the correction factor used to quantitate labeled
protein, the molecular weight of the dye and comparable commercial dyes.30 Right panel:
Excitation (black) and emission (brown) spectra for Thermo Scientific Dylight 800 dye25-26
(Figure-4).

Thermo Scientific DylightTM 800 derivatives for a broad range of applications:27-28
Dylight 800 reactive derivatives for labeling:
Amine-reactive dye (N-hydroxysuccinimide (NHS) ester-activated).27-28
Sulfhydryl-reactive dye (Maleimide-activated).27-28
Free acid dye – non reactive; used as negative control. 27-28
Dylight 800-conjugated fluorescent probes:
Secondary antibody-conjugated- Goat Anti-Mouse or Anti-Rabbit. 27-28
Streptavidin-conjugated. 27-28
Neutravidin protein-conjugated. 27-28
Additional fluorescence-based applications: 27-28

9

In-Cell ELISA Near Infrared Detection Kit. 27-28
Materials and Instrumentation used for Synthesis:
1. DyLightTM 800 Maleimide is the main product 1mg, stored at -2000C Product#46621,
Lot#KK12610414
2. DMSO: Sigma Aldrich, 99% purity; Folate Cysteine: Provided by Dr. Henne ;
Fluorescein sodium salt(C20H10Na2O5) : Lot# 079K0141V; Multichannel pipetter :
RAININ , 20-300µl;
3. UV Plates: BD Falcon microtest 96 well 370µl clear plate, UV Vis transparent film
bottom,
4. Non-sterile, no lid, lot No:E1002007; Regular Plates: Generic Bio-One, microplate,
96well flat bottom, Lot No: E091006L; Spin Filters : Sigma Aldrich, Amicon ultra 0.5
centrifugal filter,
5. 3 kDa, Batch No: 3110; PD-10 Columns: Sephadex G-25M columns, contains 0.15%
Kathon CG in DI H20, lot no. 393861; Centrifuge: Beckman CS-15R Centrifuge at 8898
RPM for 12 mins.
6. UV Plate Reader and BCA assay Software: Gen 5.1.10 Biotek, Epoch.
7. DIPEA (N,N-Diisopropylethylamine)
8. Synthesized Folate – Peptide (Folate-Asp-Arg-Asp-Asp-Cys-SH supplied by W. Henne),
DyLightTM 800 maleimide was supplied by Thermo Scientific, 99% DIPEA ( N,NDissopropylethylamine) supplied by Aldrich chemicals, DMSO ( Dimethylsulfoxide)
supplied by fischer swcientific.
9. HPLC instrumentation and UV-visible spectrophotometer.
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Method and Analysis:

Synthesis of Folate-DyLightTM 800:
1 mg DyLightTM 800 maleimide was dissolved in 200 ul dimethylsufoxide(DMSO). 2 mg
of folate peptide cysteine and 10 ul of DIPEA (N,N-Diisopropylethylamine) were added and
mixed overnight using a magnetic stirrer (at room temperature). The product was purified by
reverse phase HPLC and analyzed by LC/MS, UV-Vis spectrophotometer. The synthesis of
Folate-Dylight 800 maleimide is shown in (figure -5).

Preparation of Buffers:
Take 0.45 g of ammonium bicarbonate and add 500 ml of distilled water and then stir to
dissolve (10 mM bicarbonate buffer, pH ~ 6.8).

Experimental Parameters for HPLC:
The analysis of synthesized product was done by HPLC (Hewlett Packard, series1050)
with YMC, HPLC column with particle size 6µm and dimension 4.6 x 150 mm. Purification was
done by Rigel HPLC with particle size 5 µm and column dimension 10 x 250 mm.
Solvents used: ammonium bicarbonate/acetonitrile
Flow rate is 1 ml/min
Detector: DAD with scanning range 200-600
Method used is BIOTINRH.M
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Gradient method for Folate - Dylight conjugates purification (HPLC)

Time (min)

%B

0.00

1

1.00

1

20.0

99

40.0

99

41.0

99

50.0

99

52.0

1

60.0

1

Experimental parameters for UV-Visible Spectrophotometer:
Instrument: Epoch Microplate Spectrophotometer
U.V Plate Reader Analysis at λ = 777nm of stock containing 1:10 dilution of purified dylight 800
in PBS was conducted.
Experimental Parameters for LC/MS:
Initially sample was centrifuged for 7 mins at 12.2 p/min and supernatant sample was extracted.
Then 100 μL of folate dylight 800 was injected into LC/MS.
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Column Parameters

Mode

Positive ion mode

Flow rate

5ml/min

Solvent A

Water

Solvent B

Methanol

Column

XDB-C18

Scan range

500 – 2200 m/z

Nebulizer Pressure

40 psi

Threshold

1000

Drying gas Temperature

300C
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Competition Studies of DyLight TM 800 using FTR:

Step 1

• Test (D) : 100 μL of Dylight 800 + RPMI medium in L1210 FR cancer cells
incubated for 10 mins

• Control (R) : RPMI medium in L1210 FR cells incubated for 10 mins
Step 2

Step 3

• 10 μL FTR medium was added to both D and R and incubated for 35 mins.
Then both the tubes were centrifuged and washed with 1ml PBS thrice and
finally 10 μL of PBS was added to both the tubes.

• Slides were prepared for observation under microscope.
Step 4

Results and Discussion:
The synthesis of Folate –DyLightTM 800 was a very simple and quick method. In this
method, the folate-peptide and DyLightTM 800 was conjugated via maleimide chemistry
(thioether linkage). The synthesis method was inexpensive and can be performed in small
laboratories. The main advantage of this synthetic approach is that folate-peptide is very stable
and can be stored for a long time and can be scaled to 0.5 gram batches.
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The purification of Folate-DyLightTM 800 conjugate was accomplished using reversed
phase HPLC. Total run time was 1 hour (60 mins). For the analytical run, 10 µl injection of the
product was injected in HPLC and analyzed. Peaks were observed at 11.4 min, 15.9 min, 16.4
min, 17, 5 min, 18.6 min. From these peaks, the sample from peaks at 17.5 min and 18.6 min
were collected and stored it in the vials and these purified samples we injected 10 µl each in the
HPLC for analysis. Also UV-Vis of the collected fractions were assessed using a spectral scan in
a UV/ViS micro-plate reader. In the HPLC chromatogram, at 17.7 min we observed the
unreacted folate cysteine peak, the compound Folate-DyLight 800 peak at 21.1 min and the
unreacted dye peak at 32.3 min (Figure-6). At 18.6 min we have clearly observed few peaks
with small intensities. It is largely anticipated that the compound at 21.2 min is folate dylight 800
(Figure-7).
By using the microplate reader we observed the characteristic DyLight 800 peak at around 790
nm. We also observed the characteristic folate doublet at 280 and 363 nm. The spectrum is
displayed in Figure-8.
From LC/MS chromatogram a distinct peak at 3.252 min was observed corresponding to that of
Folate -DyLight 800 (Figure-10). Offline session was conducted and the DAD spectrum was
produced which showed the DyLight – 800 peak at 800 nm and Folate peak at 330 nm (Figure9).
Competition studies with Rhodamine showed that higher concentration of DyLight 800 competes
and binds with L1210 FR cancer cells (Figure-12). More Dylight 800 prevents FTR from
binding with folate receptors on the cancer cells. The other slide (control) showed dark red spots
of FTR binding to cancer cells (Figure-11).
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Conclusion:
Folate-DylightTM 800 was successfully synthesized by very simple, inexpensive and safe
method. The whole synthesis method can be performed in small laboratories with minimum
resources and small quantity of reagents required. The synthesis of Folate-DylightTM 800
conjugate was successfully purified by HPLC. The purified Folate-DylightTM 800 conjugate was
evaluated by LC/MS, UV-Vis and HPLC.
Competition studies of DyLightTM 800 showed that high concentrations of our dye competes
with FTR and binds to L1210 FR cancer cells.

Figures:

Source: Folic Acid - Bristol University homepage - a place for ... (n.d.). Retrieved from
http://www.chm.bris.ac.uk/webprojects2002/schnepp/folic.html

(Figure: 1) Structure of folic acid
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(Figure:2) General Scheme for Folate-Dye conjugates
Source: ScienceDirect.com - Advanced Drug Delivery Reviews - Optical ... (n.d.). Retrieved
from http://www.sciencedirect.com/science/article/pii/S0169409X05000566

Source: Christopher P. Leamon. Drug Receptor pathway. Sciencedirect.com. 17 Nov 2012.
<http://www.sciencedirect.com/science/article/pii/S135964460001944>

(Figure:3) Transportation of Folate-conjugates via Folate receptors.
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Product

Color

mass (g/mol)

Absorb (nm)

Emit (nm)

ε (M-1cm1
)

DyLight 350

violet

874

353

432

15,000

DyLight 405

violet

793

400

420

30,000

DyLight 488

green

1011

493

518

70,000

DyLight 550

yellow

982

562

576

150,000

DyLight 594

orange

1078

593

618

80,000

DyLight 633

red

1066

638

658

170,000

DyLight 650

red

1008

654

673

250,000

DyLight 680

far-red

950

692

712

140,000

DyLight 755

near-IR

1092

754

776

220,000

DyLight 800

near-IR

1050

777

794

270,000

Source: DyLight Fluor Labeling Reagents and Kits - Protein ... (n.d.). Retrieved from
http://www.piercenet.com/browse.cfm?fldID=294EFD98-4461-4352-A046-50B522F52952

Table-1 Dylight Products
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Excitation

Thermo Scientific Dylight 800 Properties
Excitation(nm)

777

Emission(nm)

794

Color

Near-IR

€†

270,000

CF‡

0.045

Mol.Weight(g/mol)

899.15

Emission

Spectrally similar Dyes Alexa Fluor*790,
IR Dye*800
†Molar extinction coefficient (M-1 cm-1)
‡ Correction factor(A260/A777)

(Figure-4) Thermo Scientific DylightTM 800
Properties

Source: DyLight Fluor Labeling Reagents and Kits - Protein ... (n.d.). Retrieved from
http://www.piercenet.com/browse.cfm?fldID=294EFD98-4461-4352-A046-50B522F52952
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+
DylightTM 800 Maleimide

Folate DylightTM 800 Maleimide conjugate
(Figure:5) Schematic Representation of Folate DylightTM 800 Maleimide conjugate
synthesis
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(Figure:6) Chromatogram of crude Folate-DylightTM 800

21

(Figure: 7) Chromatogram of purified Folate-DylightTM 800 conjugates at 21.1 min.
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DyLight 800 Peak

Folate peak
0.8

0.7

0.6

Absorbance

0.5

0.4

0.3

0.2

0.1

0
230

330

430

530

630

730

830

Wavelength, nm

(Figure: 8) UV-Vis of Folate-DylightTM 800 conjugates
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(Figure: 9) DAD spectrum of Folate DylightTM 800
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(Figure: 10) LC/MS chromatogram of Folate DyLight 800 Conjugate
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(Figure: 11) Slide R containing L1210 FR cancer cells in FTR

26

(Figure: 12) Slide D showing a light red spot due to binding of DyLightTM 800 with L1210
FR Cancer cells.
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